Halozyme Therapeutics, Inc. (HALO) belonging to the Medical sector has surged 5.92% and closed its last trading session at $14.68.
The company reported its EPS on 02/28/2017. Currently, the stock has a 1 Year Price Target of $16.
The consensus recommendation, according to Zacks Investment research, is 1.5. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.5 and 1.5 respectively.
Halozyme Therapeutics, Inc. on 02/28/2017 reported its EPS as $-0.21 with the analysts projecting the EPS of the stock as $-0.28. The company beat the analyst EPS Estimate with the difference of $0.07. This shows a surprise factor of 25%.
Many analysts have provided their estimated foresights on Halozyme Therapeutics, Inc. Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.25.
Whereas they predicted High and Low Earnings Estimate as $-0.21 and $-0.27 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.16.
Analysts are also projecting an Average Revenue Estimate for Halozyme Therapeutics, Inc. as $29.92 Million in the Current Quarter. This estimate is provided by 6 analysts.
The High Revenue estimate is predicted as 31.5 Million, while the Low Revenue Estimate prediction stands at 28 Million. The company’s last year sales total was 42.5 Million.
For the Current Quarter, the growth estimate for Halozyme Therapeutics, Inc. is -56.2%, while for the Next Quarter the stock growth estimate is -14.3%.
The Company got Downgrade by Citigroup on 6-Jan-17 from Buy to Neutral.
Insider Trades for Halozyme Therapeutics, Inc. show that the latest trade was made on 5 Feb 2017 where Torley (Helen), the Chief Executive Officer completed a transaction type “Buy” in which 31250 shares were traded at a price of $0.
Over the period of 6 months, Insider Purchases show a total of 1 transaction in which 10000 shares were traded. 1 Insider Sales transactions were made totaling 20000 shares traded.
7 analysts projected Price Targets for Halozyme Therapeutics, Inc.. The analysts believe that the company stock price could grow as high as $20. The Low Price target projection by analysts is $13 and the Mean Price Target is $16.
Halozyme Therapeutics, Inc. (HALO) has the market capitalization of $1.89 Billion. The company rocked its 52-Week High of $14.75 on Mar 16, 2017 and touched its 52-Week Low of $7.7 on Jun 27, 2016.
The stock has Return on Assets (ROA) of -35.9 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of -45.8 percent.
The stock is currently showing YTD performance of 48.58 Percent. The company has Beta Value of 2.26 and ATR value of 0.63. The Weekly and Monthly Volatility stands at 4.47% and 5.16%.